AI Article Synopsis

  • Researchers monitored the Watson-Crick GNH1 proton in the poly(dG-dC).poly(dG-dC) DNA sequence at 500 MHz, varying NaCl concentration from 1.5 to 3.6 M in a 90% H2O:10% D2O solution at 30°C.
  • The study found that the bases maintain their Watson-Crick pairing during the B-Z transition, indicating no significant base pair opening occurs.
  • The researchers also provided a detailed stereodynamical trajectory illustrating the transition from right-handed B-DNA to left-handed Z-DNA.

Article Abstract

Monitoring of the Watson-Crick GNH1 proton in poly(dG-dC).poly(dG-dC) at 500 MHz in 90% H2O:10% D2O at 30 degrees C as a function of NaCl concentration (1.5 to 3.6 M), demonstrates that the bases retain Watson-Crick pairing throughout the transition. This observation unequivocally demonstrates that during the B-Z transition there is no large scale and detectable base pair opening and that macroscopically the phenomenon can be described as a direct helix to helix transition. We present frame by frame, an energetically sound stereodynamical trajectory for this transfiguration from right-handed B-DNA to left-handed Z-DNA.

Download full-text PDF

Source
http://dx.doi.org/10.1080/07391102.1983.10507426DOI Listing

Publication Analysis

Top Keywords

b-z transition
8
transition large
8
large scale
8
500 mhz
8
scale breakage
4
breakage watson-crick
4
watson-crick base
4
base pairs
4
pairs direct
4
direct demonstration
4

Similar Publications

Rare earth elements have been shown to trigger the B-to-Z DNA transition in diverse self-assembled branched DNA architectures. Herein, we investigated the influence of cerium chloride on the conformational changes of DNA sequences containing repeated cytosine-guanine (CG) or guanine-cytosine (GC) sequences. The CD results show that (CG) repeats were susceptible to the formation of Z-DNA at low concentrations of CeCl.

View Article and Find Full Text PDF

Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases.

Therap Adv Gastroenterol

October 2024

Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Kálvária Avenue 57, Szeged H-6725, Hungary.

Article Synopsis
  • The study investigates the effectiveness, safety, and patient preferences associated with switching from intravenous to subcutaneous vedolizumab treatment for inflammatory bowel diseases over a 52-week period.
  • A total of 70 patients were included, with high rates of clinical and biochemical remission observed in both ulcerative colitis and Crohn's disease groups, while 17.1% discontinued the treatment primarily due to loss of response.
  • Overall, switching to subcutaneous administration showed effective treatment persistence, stable remission rates, and no new safety concerns.
View Article and Find Full Text PDF

Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence.

Transl Lung Cancer Res

September 2024

Department of Respiratory Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

Background: Emerging evidence has underscored the crucial role of infiltrating immune cells in the tumor immune microenvironment (TIME) of non-small cell lung cancer (NSCLC) development and progression. With the implementation of screening programs, the incidence of early-stage NSCLC is rising. However, the high risk of recurrence and poor survival rates associated with this disease necessitate a deeper understanding of the TIME and its relationship with driver alterations.

View Article and Find Full Text PDF

Endoplasmic reticulum to mitochondria Ca transfer is important for cancer cell survival, but the role of mitochondrial Ca uptake through the mitochondrial Ca uniporter (MCU) in pancreatic adenocarcinoma (PDAC) is poorly understood. Here, we show that increased MCU expression is associated with malignancy and poorer outcomes in PDAC patients. In isogenic murine PDAC models, deletion ( ) ablated mitochondrial Ca uptake, which reduced proliferation and inhibited self-renewal.

View Article and Find Full Text PDF
Article Synopsis
  • KRAS inhibitors are medicine that work against a type of pancreatic cancer called PDAC, but patients often develop resistance to these treatments.
  • When patients with a specific mutation (KRASG12C) took certain drugs, new mutations and changes were found that helped the cancer resist the treatment.
  • Using a mix of KRAS inhibitors and chemotherapy showed better results in controlling tumors in mouse models, suggesting that combining treatments might be a smarter approach for patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!